$120MSeries B, 15 October 2025
Fund the Phase III program for PP-405, planned to start in 2026
- Amount
- $120M
- Stage
- Series B
- Announced
- 15 October 2025
- Lead
- ARCH Venture Partners
- Other investors
- GV, Main Street Advisors, Visionary Ventures
- Use of funds
- Fund the Phase III program for PP-405, planned to start in 2026
- Checked
- Amount and date matched across 2 press sources
- Sources
- Pelage Pharmaceuticals raises $120M Series B (date approx) biospace.com
Pelage Pharmaceuticals raises $120M Series B (date approx) alleywatch.com